Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sikkerhed og tolerabilitet af Pirfenidon ved akut pancreatitis

27. august 2026 opdateret af: Nikhil Bush Jayaram, University of Alabama at Birmingham

Evaluering af Pirfenidon som terapi hos patienter med forventet moderat til svær akut pancreatitis

The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis. Pirfenidone is currently approved by FDA for the treatment of idiopathic pulmonary fibrosis. Now, over 5 years of data has accumulated demonstrating safety of its use in humans. The investigators' preclinical data suggest that pirfenidone is very effective in reducing the severity of acute pancreatitis in animal models. Following are the objectives of the proposed clinical trial:

Primary Objective:

  • To evaluate the safety and tolerability of pirfenidone, compared to placebo, in patients predicted to have moderately severe or severe AP.
  • To evaluate the efficacy of pirfenidone in reducing the laboratory markers of inflammation and improving patient reported outcome measures.

Secondary Objective:

- To evaluate the efficacy of pirfenidone in reducing the severity of acute pancreatitis, as measured by well-defined endpoints.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The study is a Randomized Pilot clinical trial evaluating safety and tolerability of pirfenidone in patients with predicted moderately severe to severe acute pancreatitis. There are built in secondary end-points for efficacy. The patients with acute pancreatitis, who present within 48h of establishment of the diagnosis, will be screened for exclusion and inclusion criteria and consented for the clinical trial. Patients with be randomized into placebo or pirfenidone arm and followed daily in-person, while in hospital, and by telephone once discharged from the hospital (weekly for 4 weeks, then monthly for up to 6 months) for study end points.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294
        • UAB
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Mayo Clinic

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Patients 18 - 85 years of age

  2. Admitted to hospital for AP, defined by at least 2 of the following 3:

    1. amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values
    2. characteristic cross-sectional imaging
    3. typical upper abdominal pain- acute onset of a persistent, severe, epigastric pain often radiating to the back
  3. Patients identified, approached, and consented to administer study medication or placebo within 48 hours of diagnosis of AP.

  4. Predicted to have MSAP or SAP by presence of one or more of the following criteria

    1. APACHE II ≥ 8
    2. Modified Glasgow or Imrie score ≥ 3
    3. CRP > 150 mg/dL
    4. PASS score > 140 at or within 48 hrs. of admission
    5. CT or MRI imaging suggesting pancreatic and/or peri-pancreatic necrosis

Exclusion Criteria:

  1. Age < 18 or > 85 years
  2. Body weight > 200 kg
  3. Presentation to the medical attention > 48 h after diagnosis of AP
  4. Inability to recruit, randomize and start the allocated treatment within 48h of start of pain
  5. Ongoing AP or diagnosis of AP in previous 30 days
  6. Chronic pancreatitis
  7. Known hypersensitivity to pirfenidone
  8. AST/ALT ≥ 2 times the upper normal limit.
  9. Alkaline phosphatase ≥ 2 times the upper normal limit
  10. Bilirubin higher than upper normal limit
  11. Moderate to severe heart failure and/or coronary heart disease (New York Heart Association (NYHA) Functional Class III/IV)
  12. On home oxygen or home mechanical ventilation
  13. Advanced liver disease
  14. Paralytic ileus or significant nausea and vomiting
  15. Chronic Diarrhea
  16. Immunosuppressive disorder or on immunosuppressive medications
  17. Active or advanced malignancy
  18. Known cancer that is end-stage with ongoing palliative care or for which palliative care is appropriate
  19. Known established infection prior to the onset of acute pancreatitis
  20. Known history of infective hepatitis
  21. Known live vaccines or therapeutic infectious agents within one month of admission
  22. Known pregnancy or lactation at the time of admission
  23. Ongoing photosensitivity and rash
  24. Women of childbearing potential who are not on oral or injectable contraceptives or IUDs and do not consent to practice abstinence for period of 4 weeks.
  25. Known to be currently participating in a trial testing any investigational medicinal product or participation in a clinical study involving a medicinal product in the last three months
  26. Alcohol or substance abuse in the past 2 years
  27. Family or personal history of long QT syndrome ( > 500 msec)
  28. Medications like fluvoxamine or sildanefil
  29. Significant photosensitivity or new rash
  30. Renal disease with GFR < 30
  31. Any condition other than above that, in the opinion of the investigator, is likely to result in the death of the patient within the next 2 years
  32. Any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of pirfenidone

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Placebo

The placebo tablets will be an exact replica of the pirfenidone tablet.

Eksperimentel: Pirfenidon behandling

Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Development of Anticipated or Un-anticipated Adverse Events (Class 3 or 4)
Tidsramme: 6 months

Development of anticipated or un-anticipated adverse events (class 3 or 4)

6 months
Percentage of Patients Starting and Completion of the Planned Drug Treatment
Tidsramme: 7 days

percentage of patients starting and completion of the planned drug treatment

7 days
Changes in C-reactive Protein (CRP), TNF-α, Interleukin (IL)-6, IL-8 and IL-10 Levels
Tidsramme: 7 days

Compared to base line

7 days
Percentage of Patients Having Decrease in PAN-PROMISE Score by at Least 10 Points at 72h After Initiation of the Drug
Tidsramme: 3 days

Measurement of PAN-PROMISE score

3 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cumulative PAN-PROMISE Score
Tidsramme: 7 days

total of the PAN-PROMISE over 7 days

7 days
Cumulative PASS Score
Tidsramme: duration of admission

total of PASS score during admission

duration of admission
PASS Score at the Time of Discharge
Tidsramme: duration of admission

PASS score measurement

duration of admission
Composition Outcome
Tidsramme: 6 months

total of development of new or worsening pancreatic or peri-pancreatic necrosis, death or major infection

6 months
Readmission and/or ER Visits
Tidsramme: within 30 days and within 6 months
within 30 days and within 6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. august 2023

Primær færdiggørelse (Faktiske)

26. februar 2026

Studieafslutning (Faktiske)

26. februar 2026

Datoer for studieregistrering

Først indsendt

23. marts 2022

Først indsendt, der opfyldte QC-kriterier

23. april 2022

Først opslået (Faktiske)

28. april 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. august 2026

Sidst verificeret

1. februar 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IRB-300008875
  • W81XMH2110665 (Andet bevillings-/finansieringsnummer: U.S. Department of Defense)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .